Fractyl Health (Nasdaq: GUTS) announced it will call all outstanding Tranche A common stock purchase warrants, giving holders until 6:30 p.m. ET on December 30, 2025 to exercise at $1.05 per share or accept cancellation for $0.00001 per underlying share.The company has ~17,063,073 Tranche A Warrants outstanding; full exercise would generate up to $17.9 million in gross proceeds before fees. The call was enabled after Fractyl released positive three-month randomized midpoint data from the REMAIN-1 study and met trading conditions, including an average closing price above $1.37 for 15 consecutive trading days; the last reported Nasdaq sale price on December 15, 2025 was $2.24.

CEA Industries (NASDAQ: BNC) reported fiscal Q2 2026 results for the quarter ended Oct 31, 2025, highlighting a strategic shift to a digital-asset-treasury (DAT) model.Key facts: Net income $283.6M (includes a $206.8M gain on change in fair value of warrant liability), EPS $5.36, closed a $500M private placement on Aug 5, 2025 (up to $1.25B gross if warrants exercised), launched Nasdaq ticker BNC, and began accumulating BNB tokens, surpassing 500,000 BNB.Governance and capital moves: appointed three independent directors, launched an investor dashboard, announced a $250M share repurchase program and bought 1.8M shares for $11.3M (avg $6.27), with continued plans to target owning 1% of total BNB supply.

Allogene (Nasdaq: ALLO) announced a favorable arbitration ruling that reconfirms its full development and commercial control of cemacabtagene ansegedleucel (cema-cel) in the United States, all EU member states, and the United Kingdom and clears a path to obtain full global commercialization rights from Servier.The tribunal rejected Cellectis’s claims, found milestone payments tied to the pivotal trial are due only upon FDA acceptance of a BLA, and limited license termination to the UCART19 V1 product (ALLO-501). Allogene expects a meaningful catalyst with a 1H 2026 interim futility analysis from its pivotal Phase 2 ALPHA3 trial of cema-cel in 1L consolidation for large B-cell lymphoma (LBCL).

Ovintiv (NYSE: OVV) signed a 12-year agreement for 0.5 mtpa of Pembina's liquefaction capacity at the Cedar LNG facility to enable export of 0.5 mtpa of LNG. The agreement covers transportation and liquefaction services for a 12-year term commencing with commercial operations at Cedar LNG, which are anticipated in late 2028. The arrangement gives Ovintiv additional export market access from Canada’s west coast, described as the shortest shipping route to Asian LNG markets, and complements its existing natural gas transportation portfolio.The agreement positions Ovintiv to monetize Montney gas via global LNG markets while relying on Cedar LNG reaching commercial operations on the stated timeline.

InnSuites Hospitality Trust (NYSE American: IHT) reported Hotel Revenue results surpassing $5.8 million once again in the First Three Fiscal Quarters of 2026, (February 1, 2025, to October 31, 2025), with Total Revenue of approximately $5,809,673.

ServisFirst Bank opens a Houston office to lead its Texas expansion, appointing Christopher Dvorachek as Regional CEO and building a new commercial team.

XOMA Royalty (NASDAQ: XOMA) agreed to acquire Generation Bio (NASDAQ: GBIO) for $4.2913 per share cash plus one non-transferable contingent value right (CVR) per share. The CVR entitles holders to potential pro rata payments tied to: excess net cash over $29 million; 90%–100% of lease-savings on Generation Bio’s Cambridge office (timing-dependent); up to 90% of proceeds from Generation Bio’s Moderna license milestones and royalties; and up to 70% of proceeds from any out-license or sale of Generation Bio’s ctLNP delivery platform.The transaction will begin with a tender offer within 15 business days, requires a majority tender to close, and is expected to complete in February 2026. Roughly 15% of shares are under support agreements to tender. Advisors for the parties are disclosed.

Netcapital (Nasdaq: NCPL, NCPLW) reported second quarter fiscal 2026 results for the period ended October 31, 2025 and provided a corporate update. Key financials: total revenue $51,076 vs $170,528 prior-year quarter; operating loss $2,119,457; net loss ($0.44) per share vs ($2.34) prior-year; cash $1,684,188 at October 31, 2025, up from $289,428 on April 30, 2025. The company closed an asset purchase of Rivetz on December 3, 2025 and plans to expand offerings to include cryptocurrency and blockchain financing. Management will host a business update call on Dec 16, 2025 at 10:00 a.m. ET.

Cellectis (NASDAQ: CLLS) announced an Arbitral Tribunal decision dated December 15, 2025 in its arbitration with Les Laboratoires Servier and IRIS SARL relating to the March 6, 2019 License Agreement.The Tribunal ordered a partial termination of the License Agreement with respect to product UCART19 V1 (also called ALLO-501) and provided that Cellectis shall, at Allogene’s request, engage in good-faith discussions about granting a direct license to UCART19 V1. All other claims between the parties were dismissed.

Planet Fitness enters $350M ASR with Citibank, initially receiving ~2.5M shares, and readies a new $500M repurchase program effective after ASR completion.

Combined Workhorse-Motiv targets ~$23B medium-duty EV market, gains up to $50M in new debt and 5,200-vehicle annual capacity serving major North American fleets.

First Majestic (NYSE: AG) announced expanded exploration success at its Santa Elena mine (Sonora, Mexico) and a senior management promotion on December 15, 2025. Key highlights: Santo Niño drilling (15,307 m in 32 holes) now defines mineralization >1,100 m by 400 m; Navidad drilling (10,161 m) extends mineralization >1,200 m by 400 m; Luna infill drilling (11,190 m) aims to convert Inferred to Indicated resources. Third‑party metallurgical tests show >95% Au/Ag recoveries. Company started scoping‑level mine plans and a plant expansion to increase throughput from ~3,200 to ~3,500 tpd targeted by end of 2026. Mani Alkhafaji promoted to President & Chief Corporate Development Officer.

Lightwave Logic (Nasdaq:LWLG)The company said it will grant underwriters a 30-day option to buy up to an additional 15% of shares to cover over‑allotments. All shares are being offered by the company, with Titan Partners acting as sole bookrunner. Net proceeds are planned for working capital, general corporate purposes and may be used to accelerate commercialization, expand U.S. production capacity, pursue strategic M&A, or invest in complementary technologies, though no acquisition agreements exist at this time. The offering relies on an effective Form S-3 (No. 333-281059) declared effective August 5, 2024; offering documents are available on the SEC website.

Gladstone Commercial (Nasdaq:GOOD) announced that Gladstone Commercial Limited Partnership closed an $85 million private placement of 5.99% senior unsecured notes due December 15, 2030.Proceeds will be used to repay outstanding indebtedness under its senior unsecured revolving credit facility and for general corporate purposes. The company said this is its second long-term unsecured issuance and reflects a continued move away from secured mortgage debt. Placement agents included Huntington Securities and Fifth Third Securities, with several co-placement agents and legal counsel noted.

Paramount Gold (NYSE American: PZG) reported the results of its Annual General Meeting held December 11, 2025. Of 78,338,726 shares outstanding as of October 16, 2025, 46,146,357 shares (58.91%) voted.Seven directors were re-elected for one-year terms: Rudi Fronk, Rachel Goldman, John Carden, Christopher Reynolds, Eliseo Gonzalez-Urien, Pierre Pelletier and Samantha Espley (individual vote percentages ranged from 93.56% to 98.97% for).There were 17,500,707 broker non-votes. Stockholders ratified Baker Tilly as auditor (96.57% for), approved executive compensation on an advisory basis (95.82% for), approved a 3-year say-on-pay frequency plurality (56.45% for 3 years), and approved an amendment to increase the 2016 equity plan by 2 million shares (70.68% for).

Organogenesis (Nasdaq: ORGO) announced a successful Type-B meeting with the FDA and confirmation to initiate a rolling BLA submission for ReNu planned before the end of December 2025. The company said ReNu's clinical program—two large Phase 3 randomized controlled trials, a separate 200-patient RCT, extensive commercial history, and RMAT designation—was considered appropriate for BLA submission. Management stated that, if approved, ReNu could address a significant unmet need in knee osteoarthritis, a condition affecting an estimated 31.1 million Americans, projected to reach 34.4 million by 2027.

Ark Restaurants (NASDAQ:ARKR) reported results for the fourth quarter and fiscal year ended September 27, 2025. Total revenues were $37.323M for the quarter and $165.751M for the year. Adjusted EBITDA was $(1.071M) for the quarter and $1.407M for the year. Net loss attributable to Ark was $(1.919M) for the quarter and $(11.466M) for the year (includes a $4.799M deferred tax valuation allowance).The company held $11.324M cash, $3.609M total debt, and cited ongoing litigation over its Bryant Park leases that reduced catering and a la carte revenue; the Bryant Park locations represented ~15.4% of 2025 revenue. Management will host a conference call on Dec 16, 2025 at 11:00 AM ET.

Audit committee selects Ernst & Young as 2026 auditor, pending engagement; KPMG to audit 2025 through the Form 10-K filing, with no disagreements cited.

HeartSciences reports no meaningful FQ2 2026 revenue, ends Oct. 31 with $2M cash and $4.2M equity, and submits MyoVista wavECG device for FDA 510(k).

Functional Brands (NASDAQ: MEHA) reported third quarter 2025 results for the period ended September 30, 2025.Key highlights: Revenue $1.7M (+21.4% vs Q3 2024); Gross profit +28.1% with margin improving 310 bps to 57.8%; Net income $0.3M or $0.04 per diluted share versus a net loss of $0.3M (−$0.04 per diluted share) in the year-ago quarter. The company completed a direct listing on Nasdaq under MEHA, said it achieved FIGO transparency alignment for P2i by Kirkman and early compliance with California SB 646 QR-code disclosure, and announced a commercial partnership with Market Performance Group to expand Kirkman brand eCommerce reach.

Navan (NASDAQ: NAVN) reported third quarter fiscal 2026 results for the quarter ended October 31, 2025. Revenue was $195 million, up 29% YoY. GBV grew 40% YoY to $2.6 billion and payment volume rose 12% to $1.1 billion. GAAP net loss was ($225 million) while non-GAAP net income was $9 million; non-GAAP operating margin was 13%. Customer satisfaction reached CSAT 97% and NPS 45. CFO Amy Butte will depart effective January 9, 2026; Anne Giviskos becomes interim CFO. Q4 revenue guidance: $161–$163M; FY2026 revenue guidance: $685–$687M.

RCI Hospitality Holdings (Nasdaq: RICK) filed a Form 12b-25 notifying the SEC it needs more time to file its Form 10-K for the year ended September 30, 2025; a date for the final 4Q25 and FY25 results call will be announced later.RCI reported preliminary unaudited results: Total revenues $279.4M for FY25 versus $295.6M a year earlier; Nightclubs $242.5M, Bombshells $35.8M. Cash was $33.7M and debt $235.8M at Sept 30, 2025.Corporate actions include repurchasing 72,739 shares for $2.7M (8,684,061 shares outstanding at Sept 30, 2025), later acquiring 821,000 ADW-owned shares and other purchases reducing outstanding shares to 7,812,000 as of Dec 12, 2025; sale of one club for $600k plus a $180k annual lease; and sale of 49% of Rick's Cabaret Austin for $1.8M.

Zeta Global will host an exclusive Athena fireside chat with Dan Ives, daily demos, and CES C Space and ADWEEK House sessions on AI-powered marketing.

J.Jill, Inc. today announced that it has successfully completed the refinancing of its existing credit agreement with a new $75 million senior secured five-year term loan facility. With the closing of this transaction and excluding the one-time impact of accelerated debt issuance costs, the Company expects annual cash interest expense savings of...

DENVER, Dec. 15, 2025/ PRNewswire/-- Frontier Group Holdings, Inc., parent company of Frontier Airlines, Inc., today announced that James G. Dempsey, currently the Company's President, has been appointed as Interim Chief Executive Officer, effective as of December 15, 2025. Barry L. Biffle, the Company's current Chief Executive Officer, will remain with the Company in...